Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is BlossomHill Therapeutics (BLSM) Stock Up +11.21% Today?

Why Is BlossomHill Therapeutics (BLSM) Stock Up +11.21% Today?

Key Takeaways

  • BlossomHill Therapeutics (BLSM) climbed 11.21%, or $1.53, to $15.18 on November 17, up from a prior close of $13.65, with an intraday range of $13.09 to $15.37.
  • No company press release, SEC filing, analyst rating change, or regulatory disclosure was published in conjunction with today's session.
  • The advance reverses a four-session slide that had taken shares from $16.12 on November 11 to $13.65 at Monday's close, a decline of roughly 15%.
  • Volume near 323,000 shares ran well above the roughly 215,000-share 10-day average, signaling active participation rather than a thin-order-book drift.
  • No verified sector-wide or macro catalyst explains the size of the move; price action appears specific to this low-float, recently public micro-cap.
  • News Significance Score: 15/100 — No verified company news accompanied the move, and a double-digit swing is routine for this name.
  • Traders are watching the December ASH meeting, the start of dosing in the SOLARA-2 pivotal cohort, and the approaching lock-up expiration.
  • Readers can dig into Price Targets, Earnings, and Forecast data on the dedicated pages for a fuller picture of the setup.
  • For systematic, rules-based exposure to movers like this one, explore Trending AI Robots.

Opening Summary

BlossomHill Therapeutics, Inc. (BLSM) is a San Diego-based, clinical-stage biopharmaceutical company that designs small-molecule oncology drugs. Its lead asset, BH-30643, is an OMNI-EGFR inhibitor in the Phase 1/2 SOLARA trial for EGFR-mutant non-small cell lung cancer; BH-30236, a CLK inhibitor, is in Phase 1 for relapsed AML and higher-risk MDS; and BH-501284 is a preclinical pan-KRAS candidate. The company went public in August 2026 at $16 per share and carries a market value of roughly $480 million on about 31.8 million shares.

Shares closed the November 17 session at $15.18, a gain of 11.21% from the prior close of $13.65. The direction was decisively higher, with the stock opening at $13.69 and grinding to a $15.37 high before settling near the top of the range. No verified news catalyst was found for the move.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found explains today's advance. The company's most recent substantive disclosures — the November 9 announcement of FDA alignment on a 50 mg twice-daily Phase 2 dose and pivotal SOLARA-2 design, and the November 12 third-quarter report — were both published days before this session and had already been absorbed by the market. Shares sold off after those releases, so today's action is not a delayed reaction to them.

The most plausible read is technical. BLSM had fallen 15% in four sessions and opened Tuesday near $13.09, close to the November 5 low of $11.02. A sharp bounce from that zone, on volume roughly 1.5 times the recent average, is consistent with short-covering and dip-buying in a stock with a modest free float and a habit of violent swings. Over the past 60 sessions the average absolute daily move has been about 4.8%, and seven sessions produced moves of 11.2% or more — including a 14.9% jump, an 18.4% rally, and a 13.3% decline. Today's move was roughly 2.3 times the typical daily range, sizable but not statistically rare for this name.

Market Context and Trading Activity

Participation was clearly elevated: turnover of roughly 323,000 shares compared with a 10-day average near 215,000, though still below the heaviest sessions of September and early October. There was no corresponding move in large-cap biotechnology benchmarks or in any identified peer with comparable EGFR or KRAS exposure, which reinforces that the buying was idiosyncratic rather than sector-driven.

Technically, the session carried the stock back above its 20-day average near $14.42, a level it had lost during the prior week's slide, and put distance between the price and the November low. Resistance remains in the $16.10 to $16.40 band, where the stock stalled twice in November. The move did not reclaim the 50-day trend, which still slopes lower.

News Significance Score

The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event lands at 15 out of 100.

The news component is weak: no verified development was published on the session, and the recent FDA alignment and quarterly report were already public and priced in. The price component is also moderate, not extreme. Today's 11.21% gain was about 2.3 times the stock's typical daily move, but moves of that size or larger have occurred seven times in the last 60 sessions. With only one weak component in play, the combined result stays low.

What Comes Next for BLSM

Attention now turns to the December ASH Annual Meeting, where updated BH-30236 data in relapsed AML and higher-risk MDS are scheduled for presentation — the next scheduled fundamental catalyst. Investors will also watch for confirmation that the first patient has been dosed in the registrational SOLARA-2 cohort, the event the company has flagged as the gateway to a potential accelerated approval filing.

The balance sheet remains the key risk buffer and the key constraint: roughly $224.9 million in cash against no product revenue and a quarterly net loss in the low-$20-million range, implying a runway measured in years but dependent on trial scope. A 180-day lock-up tied to the August IPO expires in early February 2027, introducing potential supply risk. Sell-side coverage established after the offering is uniformly positive, and any change in that stance — or a quiet stretch of news flow — could leave the stock to trade on technicals alone.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Bots differ widely by strategy logic, holding period, performance metrics, and the symbols they trade, so the featured lineup shifts as market conditions change. Reviewing which robots are trending can help traders see how systematic strategies are positioned right now. Visit the page to explore the current leaders and compare their approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BLSM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
10255 Science Center Drive
Phone
+1 858 732-3880
Employees
63
Web
https://www.bhtherapeutics.com
Interact to see
Advertisement
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.